288398-58-3Relevant articles and documents
A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s
Subasinghe, Nalin L.,Travins, Jeremy M.,Ali, Farah,Huang, Hui,Ballentine, Shelley K.,Marugan, Juan Jose,Khalil, Ehab,Hufnagel, Heather R.,Bone, Roger F.,Desjarlais, Renee L.,Crysler, Carl S.,Ninan, Nisha,Cummings, Maxwell D.,Molloy, Christopher J.,Tomczuk, Bruce E.
, p. 2200 - 2204 (2007/10/03)
Inhibiting the classical pathway of complement activation by attenuating the proteolytic activity of the serine protease C1s is a potential strategy for the therapeutic intervention in disease states such as hereditary angioedema, ischemia-reperfusion inj
Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
-
, (2008/06/13)
The present invention is directed to compounds of Formula I: wherein X is O, S or NR7and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.
